Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. regarding a securities fraud class action settlement, focusing on potential breaches of fiduciary duties by certain officers and directors [1][3]. Group 1: Settlement Details - A federal securities class action against Lifecore Biomedical and certain officers has reached a settlement of $3,750,000 [4]. - Shareholders who held shares before October 7, 2020, can seek corporate reforms, return of funds, and a court-approved incentive award at no cost [2][5]. Group 2: Allegations Against Lifecore - The class action complaint alleges that Lifecore made materially false and misleading statements about its business, operations, and prospects [3]. - Specific allegations include deficient internal controls over financial reporting, inaccurate financial statements requiring restatement, ineffective remediation efforts, and impaired ability to file periodic reports with the SEC [3].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified class period [1][3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable, which allowed the company to report inflated financial figures [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, resulting from a transition to a new revenue accounting system [4]. - The company also reduced its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. Group 2: Professional Liability Concerns - The lawsuit alleges that Ardent Health did not maintain sufficient professional malpractice liability insurance and that its reserves were inadequate to cover increasing claims due to social inflationary pressures in the medical malpractice sector [3]. - A $54 million increase in professional liability reserves was recorded, attributed to recent settlements and ongoing litigation in New Mexico, reflecting broader industry trends [4]. Group 3: Legal Process and Representation - Investors who purchased Ardent Health securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history at $7.2 billion in the Enron case [6].

SAN DIEGO , Jan. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CoreWeave, Inc. (NASDAQ: CRWV) securities between March 28, 2025 and December 15, 2025, inclusive (the “Class Period”), have until Friday, March 13, 2026 to seek appointment as lead plaintiff of the CoreWeave class action lawsuit. Captioned Masaitis v. CoreWeave, Inc., No. 26-cv-00355 (D.N.J.), the CoreWeave class action lawsuit charges CoreWeave and certain of CoreWeave’s ...

Core Viewpoint - Gautam Adani has engaged prominent Wall Street lawyer Robert Giuffra Jr. to defend against fraud allegations from the US Securities and Exchange Commission (SEC) as the regulator seeks to advance its stalled case [1][2]. Group 1: Legal Proceedings - The SEC's lawsuit, initiated in November 2024, accuses Gautam and Sagar Adani of violating US securities laws by making false representations regarding Adani Green Energy Ltd [3]. - The SEC has also charged the Adanis with involvement in a $250 million bribery scheme in India related to solar-power contracts [3]. - The SEC has faced challenges in formally notifying the Adanis of the lawsuit, leading to a request for alternative notification methods, including email and serving papers to other US law firms representing them [4][5]. Group 2: Market Impact - Following news of the SEC's actions, Adani stocks experienced a decline, resulting in a loss of nearly $13 billion in combined market value on January 23 [4]. Group 3: Legal Representation - Robert Giuffra Jr., a co-chair at Sullivan & Cromwell, has a history of representing high-profile clients and has been in contact with the SEC regarding the lawsuit [2][9]. - Giuffra has requested additional time to negotiate with the SEC on how to proceed with the case while both Adanis remain in India [5]. Group 4: Government Involvement - The Indian government is reportedly involved in discussions regarding the summons process, with potential modifications being considered [7]. - The Indian Ministry of Law and Justice and the Ministry of External Affairs have not yet responded to inquiries about the situation [8].

Were you affected by investment losses in VRNS common stock between February 4, 2025, and October 28, 2025? Affected Investor Losses Summary Varonis Systems, Inc. securities class action filed Purchasers or acquirers of Varonis Systems, Inc. (NASDAQ: VRNS) common stock Seeking recovery of investment losses for material misstatements and/or omissions (as alleged) from February 4, 2025 through October 28, 2025 Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) can assist at no cost to investor RADNOR, Pa., ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Regenxbio and its officers or directors following a significant stock price drop due to FDA clinical holds on its gene therapies [1][2]. Group 1: Company Overview - Regenxbio Inc. is a biotechnology company focused on gene therapy, specifically for conditions such as MPS I (Hurler syndrome) and MPS II (Hunter syndrome) [2]. - The company’s stock price fell by $2.40, or 17.9%, closing at $11.01 per share on January 28, 2026, after the announcement of the FDA's clinical holds [2]. Group 2: Regulatory Developments - The FDA placed a clinical hold on Regenxbio's investigational gene therapy RGX-111 due to a case of neoplasm in a participant from its Phase I/II study [2]. - A similar clinical hold was also placed on RGX-121, citing shared risks between the two studies [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - A class action lawsuit has been filed against Endeavor Group Holdings, Inc. for alleged securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Endeavor and certain officers and directors engaged in a scheme to depress minority bargaining power and the value for unaffiliated public shareholders [3]. - The class consists of investors who sold Endeavor Class A common stock between January 15, 2025, and March 24, 2025 [3]. - Allegations include rejecting a "majority of the minority" vote on a merger, locking in a cash-out merger consideration of $27.50 without contingencies, and disseminating misleading information regarding fairness to shareholders [3]. Group 2: Legal Representation - Pomerantz LLP is representing the class in this lawsuit and is recognized for its expertise in corporate, securities, and antitrust class litigation [4]. - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Vistagen and certain of ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Carvana Co. following a short report alleging significant overstatement of earnings and undisclosed dependencies on related parties [1][2]. Group 1: Investigation and Allegations - Pomerantz LLP is representing investors in Carvana Co. and is looking into claims of securities fraud or other unlawful business practices by the company and its executives [1]. - Gotham City Research LLC published a short report on January 28, 2026, claiming that Carvana's earnings for 2023-2024 are overstated by over $1 billion and that the company is more reliant on related parties than previously disclosed [2]. Group 2: Market Reaction - Following the allegations from Gotham City Research, Carvana's stock price dropped by $67.68, or 14.17%, closing at $410.04 per share on January 28, 2026 [2].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BellRing Brands, Inc. ("BellRing" or the "Company") (NYSE: BRBR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether BellRing and certain of its off ...